HCC non-canonical neoantigen discovery

downstream-application

HCC non-canonical neoantigen discovery: downstream-application. Finds non-canonical neoantigens in hepatocellular carcinoma by mass spectrometry-based de novo sequencing and then tests them, addressing the gap that de novo proposes…

Finds non-canonical neoantigens in hepatocellular carcinoma by mass spectrometry-based de novo sequencing and then tests them, addressing the gap that de novo proposes cryptic antigens whose immunogenicity goes unverified.

Kind	downstream-application
Deep learning	no
Acquisition	DDA
Application area	Immunopeptidomics / neoantigen

Paper describing it

• Mass spectrometry-based de novo sequencing reveals non-canonical neoantigens with antitumor efficacy in hepatocellular carcinoma (2026, JHEP Reports, peer-reviewed)

Authors (9)

Xiaohua Xing, Mingxin Liu, Jiahe Ouyang, Yaxin Tang, Baozhen Shan, Ruijing Tang, En Hu, Ming Li, Xiaolong Liu

Seen in the charts

• Application areas
• Models and the authors behind them

Back to the full map